Free tool
FAERS Monitor: Iopidine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020258 or its brand name (Iopidine, Apraclonidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
111
Serious
87
78% of reports
Hospitalization
33
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective21
- off label use7
- somnolence7
- eyelid ptosis6
- vision blurred6
- constipation5
- dry mouth5
- dyspnoea5
- eye pain5
- sinus bradycardia5
- tenderness5
- urinary retention5
- visual acuity reduced5
- acute kidney injury4
- angle closure glaucoma4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 2 |
| 2011 | 1 |
| 2014 | 8 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 13 |
| 2019 | 7 |
| 2020 | 10 |
| 2021 | 7 |
| 2022 | 8 |
| 2023 | 8 |
| 2024 | 10 |
| 2025 | 4 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,048 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| angle closure glaucomaSignal | 4 | 297.5 | 113.6 | 903 |
| eyelid ptosisSignal | 6 | 111.9 | 51.4 | 553 |
| sinus bradycardiaSignal | 5 | 98.0 | 41.6 | 388 |
| tendernessSignal | 5 | 90.9 | 38.6 | 359 |
| visual acuity reducedSignal | 5 | 28.5 | 12.1 | 107 |
| urinary retentionSignal | 5 | 28.4 | 12.1 | 106 |
| eye painSignal | 5 | 16.8 | 7.1 | 59 |
| dry mouthSignal | 5 | 11.7 | 5.0 | 39 |
| vision blurredSignal | 6 | 8.3 | 3.8 | 32 |
| somnolenceSignal | 7 | 6.6 | 3.2 | 28 |
| acute kidney injurySignal | 4 | 5.0 | 1.9 | 9 |
| constipationSignal | 5 | 4.3 | 1.8 | 10 |
| drug ineffectiveSignal | 21 | 3.0 | 2.1 | 28 |
| dyspnoea | 5 | 1.7 | 0.7 | 1 |
| off label use | 7 | 1.5 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.